title: Should aspirin be used for the primary prevention of cardiovascular disease in people with diabetes?
authors.forename: Robyn L
authors.initials: RL
authors.lastname: Woods
authors.forename: Andrew M
authors.initials: AM
authors.lastname: Tonkin
authors.forename: Mark R
authors.initials: MR
authors.lastname: Nelson
authors.forename: Helena C
authors.initials: HC
authors.lastname: Britt
authors.forename: Christopher M
authors.initials: CM
authors.lastname: Reid
mesh_terms: D000368:Aged; D001241:Aspirin / Q000008:administration & dosage*; D002318:Cardiovascular Diseases / Q000150:complications / Q000517:prevention & control*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage*; D011322:Primary Prevention / Q000379:methods*; D016896:Treatment Outcome
chemical_list: D010975:Platelet Aggregation Inhibitors; D001241:Aspirin